Spark Therapeutics is focused on developing gene therapy to accelerate healthcare transformation. It combines a proprietary adeno-associated viral (AAV) gene therapy platform with research and development, manufacturing, and commercial operations.

Spark Therapeutics

Viewport Meta

IPhone / Mobile Compatible

Domain Not Resolving

Google Tag Manager

Google Analytics

DNSSEC

Content Delivery Network

WordPress

Global Site Tag

Font Awesome

Chief Medical Officer

Gallia Levy

President and Head of R&D

Katherine High

Chief People Officer

Lisa Dalton

SVP/Head of Product Strategy

Chris Stevens

Vice President - Head of Manufacturing

Eric Hacherl

Business Management

Renuka Pillutla

Marketing and Product

Adam Beres

Associate Director, HR Technology & Programs

Alicia Bate

Senior Director, Commercial Development

Amy MacDougall

Information Technology

Amy Shillingford

Lota Zoth

Federico Mingozzi

Chief Scientific Officer

Gallia G. Levy

Junwei Sun

Co-Founder

Marcelyne Joseney-Antoine

Clinical Operations Lead, Hematolog

Michael Retterath

Chief Strategy Officer

Jennifer Flaisher

Sylke Poehling

Paul Savidge

Chief Legal Officer

Companies With More Than $100M in Revenue (Top 10K)

Northeastern US Companies With More Than 50 Employees (Top 10K)

United States Acquired Companies With More Than $1B in Revenue

Biotechnology Acquired Companies With More Than $10M in Revenue

Spark Therapeutics is developing potentially curative, one-time gene therapy products to transform the lives of patients and re-imagine the treatment of debilitating diseases. 

The founding team includes scientists who have led the advancement of gene therapy over the past two decades, establishing human proof of concept of the expression of gene therapy in the eye and liver. 

Spark’s robust pipeline includes SPK-RPE65, a fully enrolled, pivotal Phase 3 program in blindness due to mutations in the RPE65 gene, SPK-CHM for the treatment of choroideremia, and SPK-FIX, a program for the potential treatment of hemophilia B through a global collaboration with Pfizer Inc., as well as preclinical programs to address neurodegenerative diseases and other retinal degenerative diseases and hematologic disorders. 

Spark has rights to a proprietary manufacturing platform that has a track record supporting clinical studies across diverse therapeutic areas and routes of administration. 

Spark’s expertise across research, clinical, regulatory and manufacturing builds on a legacy of innovation and excellence in gene therapy established by Spark’s team while at The Children’s Hospital of Philadelphia Center for Cellular and Molecular Therapeutics.

Post-IPO Equity - Spark Therapeutics

Sofinnova Investments

Series B - Spark Therapeutics

The Children's Hospital of Philadelphia

Series A - Spark Therapeutics

Medical and Beauty Services and Agricultural Services

Philadelphia

Pennsylvania

United States

North America

Eight areas where gene therapy shines

Philly’s tech and innovation ecosystem runs on collaboration

Preclinical data on SPK-10001 AAV-based gene therapy released

Swing States Are Also In The Middle For Startup Funding

Philadelphia Power Moves: Spark Therapeutics gets a new CEO

Spark Therapeutics trimming staff, product development programs

Inherited Retinal Disease Market Size and Share to Grow by 2034, Assesses DelveInsight | Key Companies - Spark ...

Former Spark Therapeutics exec sues company over alleged sex discrimination, retaliation

Pfizer scores FDA nod for hemophilia B gene therapy, will charge $3.5M per dose

An investigational gene therapy for hemophilia A, aiming to address blood coagulation deficiencies due to mutations in the F8 gene.

A bio-engineered AAV vector for hemophilia B, utilizing a high-activity F9 transgene to potentially correct factor IX deficiency.

An investigational gene therapy for Pompe disease, targeting loss of function mutations in the gene encoding acid alpha-glucosidase (GAA).

A potential gene therapy targeting the ABCA4 gene mutation, the leading cause of inherited juvenile macular degeneration.

Developing a gene therapy for Huntington’s disease, focusing on the progressive breakdown of nerve cells in the brain.

Research programs using AAV vectors targeting the retina, liver, and central nervous system for various genetic diseases.

India

Asia

Latvia

Europe

Philippines

Hong Kong

HTML5

DigiCert

Amazon EC2

Google Maps API

F5 NGINX

Google Compute Engine

Adobe Fonts

.NET 4.5

Microsoft Outlook

Amazon Route 53

news_impact_assignment_basic

key_people

merger_acquisitions

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

customer_profile

peers

news_basic

valuation

news impact assignment basic	general
public peers	general	Sep 23, 2024 9:12 PM	1ef7b656
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general	Sep 23, 2024 9:12 PM	e0c9ba7d
crunchbase trigger	general	Nov 25, 2024 9:09 AM	e48fbc18
crunchbase profile	general	Nov 25, 2024 11:21 AM	bd2fa23f
li profile	general
translate crunchbase fundingrounds	general	Nov 25, 2024 2:27 PM	3fdf2e80
peers	general	Sep 23, 2024 9:12 PM	c03f7c82
news basic	general	Sep 23, 2024 9:12 PM	ae0d4672
bundesanzeiger	filings
financials download nd	financials
private financials	financials

COM:SPARKTX

Spark Therapeutics